Work

POSTER: MM-263: Reduced-Frequency Dosing of FDA-Approved Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Systematic Review of Maintaining Efficacy While Reducing Infection-Related Toxicity

Year: 2026

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(26)01298-x

Authors: Mahboob Younus Shaik, Sana Dugan, Ashley Jenkins

Institution: CHI St. Vincent

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7204732370

FWCI:

Cites:

Cited by:

Related to: 10